2019
Incorporating Tumor Characteristics to Maximize 21-Gene Assay Utility: A Cost-Effectiveness Analysis.
Wang SY, Chen T, Dang W, Mougalian SS, Evans SB, Gross CP. Incorporating Tumor Characteristics to Maximize 21-Gene Assay Utility: A Cost-Effectiveness Analysis. Journal Of The National Comprehensive Cancer Network 2019, 17: 39-46. PMID: 30659128, DOI: 10.6004/jnccn.2018.7077.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsChemotherapy, AdjuvantClinical Decision-MakingConnecticutCost-Benefit AnalysisDecision Support TechniquesFemaleGene Expression ProfilingGenetic TestingHumansMarkov ChainsMastectomyMiddle AgedModels, StatisticalNeoplasm Recurrence, LocalPrevalencePrognosisQuality-Adjusted Life YearsRisk AssessmentConceptsIncremental cost-effectiveness ratioClinical risk groupsQuality-adjusted life yearsHigh-risk groupLow-risk groupOncotype DXRisk groupsBreast cancerLymph node-negative breast cancerDifferent clinical risk groupsLow-risk breast cancerNode-negative breast cancerIntermediate-risk groupRecurrence score (RS) distributionConnecticut Tumor RegistryER-positive diseaseUS payer perspectivePopulation-based dataCost-effectiveness ratioProbabilistic sensitivity analysesCost-effectiveness analysisODX resultsClinical characteristicsMost patientsPatient age
2017
Cost-Effectiveness of Multidisciplinary Management Program and Exercise Training Program in Heart Failure
Dang W, Yi A, Jhamnani S, Wang SY. Cost-Effectiveness of Multidisciplinary Management Program and Exercise Training Program in Heart Failure. The American Journal Of Cardiology 2017, 120: 1338-1343. PMID: 28842145, DOI: 10.1016/j.amjcard.2017.06.071.Peer-Reviewed Original ResearchConceptsMultidisciplinary management programIncremental cost-effectiveness ratioUsual careLife yearsHeart failureExercise training programHealthcare payer perspectiveCost-effectiveness ratioProbabilistic sensitivity analysesCost-effectiveness thresholdCurrent cost-effectiveness thresholdsPayer perspectiveHealthcare costsHealth outcomesTraining programSocietal perspectiveSignificant healthFinancial burdenPatientsManagement programETPFailureYearsCare
2010
Incorporating margin status information in treatment decisions for women with ductal carcinoma in situ: a decision analysis
Wang SY, Kuntz K, Tuttle T, Kane R. Incorporating margin status information in treatment decisions for women with ductal carcinoma in situ: a decision analysis. Breast Cancer Research And Treatment 2010, 124: 393-402. PMID: 20848183, DOI: 10.1007/s10549-010-1166-7.Peer-Reviewed Original ResearchMeSH KeywordsBreast NeoplasmsCarcinoma, Intraductal, NoninfiltratingDecision Support TechniquesFemaleHumansMarkov ChainsMastectomy, SegmentalMiddle AgedNeoplasm Recurrence, LocalPatient PreferencePatient SelectionQuality-Adjusted Life YearsRadiotherapy, AdjuvantRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeConceptsBreast-conserving surgeryQuality-adjusted life yearsRadiation therapyMargin statusDuctal carcinomaRT side effectsDecision-analytic Markov modelOne-way sensitivity analysesImportance of patientsProbabilistic sensitivity analysesDCIS treatmentInvasive recurrenceSalvage mastectomyOptimal treatmentHypothetical cohortTreatment decisionsLifetime horizonSide effectsLife yearsDCISPatientsWomenCarcinomaTreatment